Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.

Literature DB >> 2736226

Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.

S Merry¹, P Flanigan, E Schlick, R I Freshney, S B Kaye.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2736226 PMCID： PMC2246748 DOI： 10.1038/bjc.1989.189

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

× No keyword cloud information.

9 in total

1. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

Authors: J Carmichael; W G DeGraff; A F Gazdar; J D Minna; J B Mitchell
Journal: Cancer Res Date: 1987-02-15 Impact factor: 12.701

2. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

Authors: G Neugebauer
Journal: Cardiovasc Res Date: 1978-04 Impact factor: 10.787

Review 3. Tumour cell resistance to anthracyclines--a review.

Authors: S Kaye; S Merry
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

4. Phase I study of vinblastine and verapamil given by concurrent iv infusion.

Authors: A B Benson; D L Trump; J M Koeller; M I Egorin; E A Olman; R S Witte; T E Davis; D C Tormey
Journal: Cancer Treat Rep Date: 1985 Jul-Aug

5. The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog.

Authors: S R Hamann; G D Todd; R G McAllister
Journal: Pharmacology Date: 1983 Impact factor: 2.547

6. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors: R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal: J Clin Oncol Date: 1987-04 Impact factor: 44.544

7. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

Authors: L M Slater; S L Murray; M W Wetzel; R M Wisdom; E M DuVall
Journal: J Clin Invest Date: 1982-11 Impact factor: 14.808

8. Cross-resistance to cytotoxic drugs in human glioma cell lines in culture.

Authors: S Merry; S B Kaye; R I Freshney
Journal: Br J Cancer Date: 1984-12 Impact factor: 7.640

9. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

Authors: M Dowsett; A L Harris; R Stuart-Harris; M Hill; B M Cantwell; I E Smith; S L Jeffcoate
Journal: Br J Cancer Date: 1985-10 Impact factor: 7.640

9 in total

11 in total

1. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.

Authors: G H Mickisch; M A Noordzij; A vd Gaast; P Gebreamlack; K U Köhrmann; E Mogler-Drautz; H Kupper; F H Schröder
Journal: J Cancer Res Clin Oncol Date: 1995 Impact factor: 4.553

2. Biochemical and ultrastructural studies on the effect of verapamil on formation and secretion of lipoproteins in rat hepatocyte suspensions.

Authors: H Franke; D Müller; B Schlag; T Zimmermann; R Dargel
Journal: Arch Toxicol Date: 1990 Impact factor: 5.153

10. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.

Authors: R Milroy
Journal: Br J Cancer Date: 1993-10 Impact factor: 7.640

Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.

1. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

2. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

Review 3. Tumour cell resistance to anthracyclines--a review.

4. Phase I study of vinblastine and verapamil given by concurrent iv infusion.

5. The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog.

6. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

7. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

8. Cross-resistance to cytotoxic drugs in human glioma cell lines in culture.

9. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

1. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.

2. Biochemical and ultrastructural studies on the effect of verapamil on formation and secretion of lipoproteins in rat hepatocyte suspensions.

3. R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.

4. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

5. Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

6. Verapamil and hematoporphyrin derivative for tumour destruction by photodynamic therapy.

7. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.

8. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.

9. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.

10. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.